RCC Prognostics and Diagnostics Highlights from SUO 2024

Dan Joyce, MD, of Vanderbilt University Medical Center, highlights key studies in renal cell carcinoma diagnostics and prognostics from the recent Society of Urologic Oncology 2024 annual meeting. Dr. Joyce explores innovative research from the conference, including the use of circulating tumor DNA for recurrence risk, point-of-care urinalysis as a prognostic tool, advancements in patient-derived organoids for personalized medicine, the role of PSMA expression in RCC, and a new recurrence risk calculator for IVC thrombectomy cases.

Abstracts referenced: 

Oncological Outcomes of Radical Nephrectomy with Venous Thrombectomy for Renal Cell Carcinoma and Development of a Recurrence Risk Calculator

Patient-Derived Renal Cell Cancer Organoids as a Model to Assess Therapeutic Targets andTreatment Resistance Mechanisms

PSMA Expression is Inversely Associated With Metastatic Progression Following Surgery in Clinically Localized Renal Cell Carcinoma

Point of Care Urinalysis in Patients With Renal Cell Carcinoma Has Prognostic Value

Tumor Characteristics Associated with Preoperatively Detectable Tumor-InformedCirculating Tumor DNA in Patients With Renal Masses Suspicious for RCC